Summary

The global Gene Cloning Service market is projected to grow from US$ 892 million in 2025 to US$ 1558 million by 2032, at a CAGR of 8.4% (2026-2032), driven by critical product segments and diverse end‑use applications.
Gene Cloning Service refers to outsourced molecular biology services in which a commercial provider constructs a customer-specified recombinant DNA molecule or plasmid from a target sequence, existing DNA template, plasmid backbone, or functional design. The service typically combines PCR amplification or de novo gene synthesis with restriction-ligation cloning, seamless assembly, Gibson-type assembly, Golden Gate assembly, recombination cloning, multi-fragment assembly, subcloning, or site-directed mutagenesis, followed by bacterial transformation, clone screening, plasmid preparation, sequence verification, and quality control. The primary deliverables are sequence-verified recombinant plasmids, corresponding bacterial stocks, plasmid maps, sequence files, and associated QC documentation. Gene Cloning Service is used across basic and functional genomics research, recombinant protein and antibody engineering, synthetic biology, genome editing, viral-vector research, cell and gene therapy discovery, vaccine and nucleic-acid therapeutic R&D, and agricultural and industrial biotechnology. The market scope focuses on commercially contracted sequence-to-construct and template-to-construct workflows in which molecular cloning and verified construct delivery represent the core service value.
Key Findings
North America remains the principal high-value market and global platform center, while China has one of the deepest regional supplier pools
Gene Synthesis & Cloning and Custom Vector Construction are key value-creating service segments
Customer demand is shifting from basic cloning toward sequence-verified, automated and increasingly complex DNA constructs
Pricing remains highly project-dependent, with construct complexity, sequence characteristics and workflow requirements driving substantial ASP dispersion
Market Trends
Gene Cloning Service is moving from conventional labor-intensive PCR, restriction-ligation and manual clone screening toward integrated, digitally ordered gene-to-construct workflows. Gene synthesis is increasingly combined directly with cloning, sequence optimization, vector design and downstream application readiness, reducing the commercial distinction between traditional molecular cloning and synthetic DNA services. At the higher end of the market, competitive differentiation is shifting toward longer DNA constructs, difficult sequences, multi-fragment assemblies, high-throughput projects, automated quality control and shorter turnaround times. In September 2026, IDT and Ansa expanded integrated ordering of complex clonal DNA constructs up to 50 kb and reported adoption by more than 400 institutions across 33 countries, illustrating the increasing commercial viability of directly manufactured sequence-verified constructs. At the same time, leading service platforms are investing in automation and AI-enabled production; GenScript reported further automation of its Life Science Group production network, reinforcing the longer-term shift from laboratory-style project execution toward scalable molecular engineering infrastructure.
Market Dynamics
Drivers
Growth in Gene Cloning Service is supported by sustained outsourcing of molecular biology workflows by pharmaceutical, biotechnology and academic customers, increasing numbers of engineered DNA constructs required for protein and antibody discovery, expansion of synthetic biology and genome-editing research, and greater demand for faster research cycles. Outsourcing is particularly attractive when customers need sequence optimization, difficult-gene synthesis, vector redesign, multi-fragment assembly and complete sequence verification in one workflow. As experimental programs generate larger numbers of variants and constructs, automation and standardized digital ordering also improve the economic case for external providers relative to maintaining equivalent specialized capacity internally.
Restraints
The most important restraint is continuing commoditization of basic cloning. Standard subcloning and simple plasmid construction have relatively low technological barriers, and intense competition among regional providers limits pricing power. Direct DNA synthesis technologies are also reducing the number of intermediate cloning steps required for some projects, placing additional pressure on conventional workflows. Project economics can be affected by difficult sequences, repetitive regions, high or low GC content, plasmid instability, toxic genes and unsuccessful transformations, which increase rework rates and complicate standardized turnaround commitments. The fragmented service structure and substantial differences in technical capability also make pricing and service-level comparison difficult for customers.
Opportunities
The strongest opportunities are shifting toward complex and higher-value molecular engineering rather than routine clone transfer. Long and difficult DNA constructs, multi-fragment assemblies, custom expression vectors, gene-editing constructs, viral-vector plasmids, large construct libraries and integrated gene-to-protein workflows provide greater differentiation and generally lower price sensitivity. Cell and gene therapy research, synthetic biology and AI-enabled protein design are increasing the number and complexity of engineered DNA sequences entering experimental workflows. Regional manufacturing is another opportunity as pharmaceutical and biotechnology customers place greater emphasis on turnaround time, data security and supply-chain resilience. VectorBuilder’s 2026 plan to invest US$50 million in an advanced biomanufacturing and R&D center in Chicago reflects this movement toward geographically distributed service and production capacity.
Challenges
Gene Cloning Service providers face simultaneous pressure to improve speed, construct complexity, sequence accuracy, cybersecurity and biosecurity compliance while keeping routine service prices competitive. Increasing automation requires capital investment in DNA synthesis, liquid handling, sequencing, informatics and quality systems, which may widen the capability gap between global platforms and smaller laboratories. Biosecurity screening is also becoming a more important operating requirement for providers handling synthetic nucleic acids. In the United States, the May 2025 executive order directed revision or replacement of the federal nucleic-acid synthesis screening framework and emphasized comprehensive, scalable and verifiable screening mechanisms, increasing the strategic importance of compliant order screening, customer verification and data-management systems.
Value Chain Analysis
The Gene Cloning Service value chain begins with upstream DNA sequences, plasmid backbones, oligonucleotides, synthetic gene fragments, enzymes, competent cells, culture media, sequencing reagents and laboratory automation systems. Digital sequence design, codon optimization, construct design and manufacturability assessment increasingly sit at the front of the workflow and influence both project success rates and downstream production costs. The midstream service provider performs DNA preparation or synthesis, molecular assembly, bacterial transformation, clone screening, plasmid preparation, sequencing and QC before delivering a verified construct. More advanced providers integrate these activities with automated ordering, biosecurity screening, sample tracking and laboratory information systems.
Value creation increasingly shifts from basic laboratory execution toward design capability, first-pass synthesis and assembly success, automation, difficult-sequence handling and validated downstream usability. Routine cloning remains price competitive and comparatively labor intensive, whereas complex vector engineering and long or multi-fragment constructs can generate higher value per project because they require greater design expertise, troubleshooting and analytical verification. Downstream customers include academic institutions, biotechnology companies, pharmaceutical companies, CRO/CDMO organizations and agricultural or industrial biotechnology developers, with the highest strategic value generally arising when cloning services are embedded within broader protein engineering, genome-editing, synthetic-biology or gene-delivery workflows.
Segment Insights
By service type, Gene Synthesis & Cloning and Custom Vector Construction represent the most commercially important value-creation directions, while PCR/template-based cloning and conventional subcloning remain foundational services for routine research. Integrated gene synthesis and cloning benefits from the ability to start from a digital sequence rather than a physical template, enabling sequence optimization and construct redesign to be completed within the same commercial workflow. Custom vector construction carries additional value where customers require promoter replacement, tag insertion, regulatory-element modification, gene-editing components or application-specific expression systems. Mutagenesis and construct modification form another recurring segment, particularly for protein engineering and functional studies.
By project complexity, the market is gradually shifting toward multi-fragment assemblies, long or difficult DNA sequences and high-throughput construct projects. These categories account for a disproportionately important share of technical differentiation because standardized cloning protocols alone are insufficient to guarantee successful delivery. Service providers with stronger DNA design, automated assembly and sequencing capabilities are therefore better positioned to capture complex projects, while smaller regional laboratories remain competitive in standard subcloning, PCR cloning and flexible low-volume custom work.
Downstream Market Opportunities
The largest addressable demand base comes from life-science research and biopharmaceutical R&D, but incremental value creation is increasingly associated with applications requiring larger numbers or more sophisticated DNA constructs. Protein and antibody engineering requires repeated generation of expression constructs and variants, while synthetic biology and metabolic engineering create demand for multi-gene pathway assemblies and high-throughput construct libraries. Genome editing, viral-vector research and cell and gene therapy development increase requirements for customized donor templates, transfer plasmids and engineered vector backbones. The expansion of AI-assisted protein and antibody design may further increase construct throughput because computationally generated candidate sequences still require physical DNA construction and experimental validation, making Gene Cloning Service an enabling layer between digital biological design and wet-lab testing.
Regional Insights
North America is the principal high-value market for Gene Cloning Service and the center of many globally scaled DNA synthesis and molecular-engineering platforms, supported by a dense pharmaceutical, biotechnology, synthetic-biology and research customer base. The region has particular strengths in automation, high-throughput gene synthesis, complex DNA manufacturing and digitally integrated ordering. Europe maintains a meaningful specialized supplier base, particularly in complex gene synthesis, plasmid engineering and customized molecular biology services, with Germany, France, Belgium and neighboring biotechnology clusters supporting numerous specialist providers.
China has developed one of the deepest regional supplier ecosystems and combines large gene-service platforms with a substantial number of flexible regional molecular-biology providers. Competition is relatively intense in standard gene synthesis, PCR cloning and vector construction, while leading domestic suppliers are moving toward higher-complexity constructs, automated production and integrated gene-to-protein services. Japan and South Korea maintain smaller but technically established domestic markets, while India has a relatively fragmented pool of cost-oriented CRO and molecular-biology providers. Southeast Asia remains smaller in direct manufacturing depth, with Singapore functioning primarily as a regional research and service hub.
Competitive Landscape Analysis
The global Gene Cloning Service market has a two-layer competitive structure consisting of a limited number of globally scaled DNA-engineering platforms and a much broader group of regional and specialized service providers. GenScript, Danaher through IDT, Twist Bioscience, Thermo Fisher Scientific through GeneArt, Azenta through GENEWIZ and Eurofins through Blue Heron operate broad gene-synthesis and molecular-engineering platforms with advantages in automation, throughput, global customer access and integrated workflows, while companies such as VectorBuilder, ATUM, Tsingke Biotechnology, Synbio Technologies, Bio Basic, Biomatik, OriGene, Macrogen, Bioneer and other confirmed regional providers compete through specialized vector capabilities, difficult-sequence handling, faster local delivery or cost efficiency. The Core Formal List is therefore materially smaller than the broad supplier pool because many CROs perform cloning internally without offering it as a clearly standardized standalone commercial service. Competitive investment is increasingly directed toward complex DNA, workflow automation, regional capacity and integrated downstream applications. GenScript has continued to expand automated production, while VectorBuilder’s planned Chicago investment illustrates the move toward localized advanced manufacturing and customer proximity. Over time, competition in routine cloning is likely to remain price-driven, whereas sustainable differentiation should increasingly depend on construct complexity, first-pass success, turnaround reliability, automation, biosecurity compliance and integration with downstream research workflows.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Gene Cloning Service market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
GenScript Biotech Corporation
Danaher
Twist Bioscience
Thermo Fisher
Azenta
Tsingke Biotechnology
VectorBuilder
Synbio Technologies
General Biol
ATUM
Bio Basic
Biomatik
OriGene
Macrogen
abm
GeneCopoeia
Bioneer
FASMAC
ProteoGenix
GeneCust
Charles River
Creative Biogene
BIONICS
Genosphere
Cosmogenetech
trenzyme
PlasmidFactory
Oriental Yeast
Protein Express
UNITECH
Synplogen
Tri-i Biotech
1st BASE
Wuhan GeneCreate
Genome Meditech
Hanbio
NewOneBio
Aragen
Barcode Biosciences
Segment by Type
Template-based Cloning
Subcloning
Gene Synthesis and Cloning
Custom Vector Construction
Others
Segment by Project Complexity
Standard Cloning
Custom Vector Modification
Multi-fragment Assembly
Difficult DNA Constructs
High-throughput Construct Projects
Segment by Construct Type
Standard Cloning Plasmids
Protein Expression Vectors
Reporter and Functional Vectors
Gene Editing Constructs
Viral Vector Plasmids
Segment by Application
Basic and Functional Research
Protein and Antibody Engineering
Synthetic Biology and Metabolic Engineering
Others
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Gene Cloning Service study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Gene Cloning Service: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Gene Cloning Service Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Template-based Cloning
1.2.3 Subcloning
1.2.4 Gene Synthesis and Cloning
1.2.5 Custom Vector Construction
1.2.6 Others
1.3 Market Segmentation by Project Complexity
1.3.1 Global Gene Cloning Service Market Size by Project Complexity, 2021 vs 2025 vs 2032
1.3.2 Standard Cloning
1.3.3 Custom Vector Modification
1.3.4 Multi-fragment Assembly
1.3.5 Difficult DNA Constructs
1.3.6 High-throughput Construct Projects
1.4 Market Segmentation by Construct Type
1.4.1 Global Gene Cloning Service Market Size by Construct Type, 2021 vs 2025 vs 2032
1.4.2 Standard Cloning Plasmids
1.4.3 Protein Expression Vectors
1.4.4 Reporter and Functional Vectors
1.4.5 Gene Editing Constructs
1.4.6 Viral Vector Plasmids
1.5 Market Segmentation by Application
1.5.1 Global Gene Cloning Service Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Basic and Functional Research
1.5.3 Protein and Antibody Engineering
1.5.4 Synthetic Biology and Metabolic Engineering
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Gene Cloning Service Revenue Estimates and Forecasts (2021-2032)
2.2 Global Gene Cloning Service Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Gene Cloning Service Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Gene Cloning Service Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Template-based Cloning: Market Share by Key Players
3.3.2 Subcloning: Market Share by Key Players
3.3.3 Gene Synthesis and Cloning: Market Share by Key Players
3.3.4 Custom Vector Construction: Market Share by Key Players
3.3.5 Others: Market Share by Key Players
3.4 Global Gene Cloning Service Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Gene Cloning Service Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Gene Cloning Service Market by Project Complexity
4.2.1 Global Revenue by Project Complexity (2021-2032)
4.2.2 Global Revenue-Based Market Share by Project Complexity (2021-2032)
4.3 Global Gene Cloning Service Market by Construct Type
4.3.1 Global Revenue by Construct Type (2021-2032)
4.3.2 Global Revenue-Based Market Share by Construct Type (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Gene Cloning Service Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Gene Cloning Service Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Gene Cloning Service Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Gene Cloning Service Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Gene Cloning Service Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Gene Cloning Service Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Gene Cloning Service Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Gene Cloning Service Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Gene Cloning Service Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Gene Cloning Service Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Gene Cloning Service Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 GenScript Biotech Corporation
11.1.1 GenScript Biotech Corporation Corporation Information
11.1.2 GenScript Biotech Corporation Business Overview
11.1.3 GenScript Biotech Corporation Gene Cloning Service Product Features and Attributes
11.1.4 GenScript Biotech Corporation Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.1.5 GenScript Biotech Corporation Gene Cloning Service Revenue by Product in 2025
11.1.6 GenScript Biotech Corporation Gene Cloning Service Revenue by Application in 2025
11.1.7 GenScript Biotech Corporation Gene Cloning Service Revenue by Geographic Area in 2025
11.1.8 GenScript Biotech Corporation Gene Cloning Service SWOT Analysis
11.1.9 GenScript Biotech Corporation Recent Developments
11.2 Danaher
11.2.1 Danaher Corporation Information
11.2.2 Danaher Business Overview
11.2.3 Danaher Gene Cloning Service Product Features and Attributes
11.2.4 Danaher Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.2.5 Danaher Gene Cloning Service Revenue by Product in 2025
11.2.6 Danaher Gene Cloning Service Revenue by Application in 2025
11.2.7 Danaher Gene Cloning Service Revenue by Geographic Area in 2025
11.2.8 Danaher Gene Cloning Service SWOT Analysis
11.2.9 Danaher Recent Developments
11.3 Twist Bioscience
11.3.1 Twist Bioscience Corporation Information
11.3.2 Twist Bioscience Business Overview
11.3.3 Twist Bioscience Gene Cloning Service Product Features and Attributes
11.3.4 Twist Bioscience Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.3.5 Twist Bioscience Gene Cloning Service Revenue by Product in 2025
11.3.6 Twist Bioscience Gene Cloning Service Revenue by Application in 2025
11.3.7 Twist Bioscience Gene Cloning Service Revenue by Geographic Area in 2025
11.3.8 Twist Bioscience Gene Cloning Service SWOT Analysis
11.3.9 Twist Bioscience Recent Developments
11.4 Thermo Fisher
11.4.1 Thermo Fisher Corporation Information
11.4.2 Thermo Fisher Business Overview
11.4.3 Thermo Fisher Gene Cloning Service Product Features and Attributes
11.4.4 Thermo Fisher Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.4.5 Thermo Fisher Gene Cloning Service Revenue by Product in 2025
11.4.6 Thermo Fisher Gene Cloning Service Revenue by Application in 2025
11.4.7 Thermo Fisher Gene Cloning Service Revenue by Geographic Area in 2025
11.4.8 Thermo Fisher Gene Cloning Service SWOT Analysis
11.4.9 Thermo Fisher Recent Developments
11.5 Azenta
11.5.1 Azenta Corporation Information
11.5.2 Azenta Business Overview
11.5.3 Azenta Gene Cloning Service Product Features and Attributes
11.5.4 Azenta Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.5.5 Azenta Gene Cloning Service Revenue by Product in 2025
11.5.6 Azenta Gene Cloning Service Revenue by Application in 2025
11.5.7 Azenta Gene Cloning Service Revenue by Geographic Area in 2025
11.5.8 Azenta Gene Cloning Service SWOT Analysis
11.5.9 Azenta Recent Developments
11.6 Tsingke Biotechnology
11.6.1 Tsingke Biotechnology Corporation Information
11.6.2 Tsingke Biotechnology Business Overview
11.6.3 Tsingke Biotechnology Gene Cloning Service Product Features and Attributes
11.6.4 Tsingke Biotechnology Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.6.5 Tsingke Biotechnology Recent Developments
11.7 VectorBuilder
11.7.1 VectorBuilder Corporation Information
11.7.2 VectorBuilder Business Overview
11.7.3 VectorBuilder Gene Cloning Service Product Features and Attributes
11.7.4 VectorBuilder Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.7.5 VectorBuilder Recent Developments
11.8 Synbio Technologies
11.8.1 Synbio Technologies Corporation Information
11.8.2 Synbio Technologies Business Overview
11.8.3 Synbio Technologies Gene Cloning Service Product Features and Attributes
11.8.4 Synbio Technologies Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.8.5 Synbio Technologies Recent Developments
11.9 General Biol
11.9.1 General Biol Corporation Information
11.9.2 General Biol Business Overview
11.9.3 General Biol Gene Cloning Service Product Features and Attributes
11.9.4 General Biol Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.9.5 General Biol Recent Developments
11.10 ATUM
11.10.1 ATUM Corporation Information
11.10.2 ATUM Business Overview
11.10.3 ATUM Gene Cloning Service Product Features and Attributes
11.10.4 ATUM Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Bio Basic
11.11.1 Bio Basic Corporation Information
11.11.2 Bio Basic Business Overview
11.11.3 Bio Basic Gene Cloning Service Product Features and Attributes
11.11.4 Bio Basic Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.11.5 Bio Basic Recent Developments
11.12 Biomatik
11.12.1 Biomatik Corporation Information
11.12.2 Biomatik Business Overview
11.12.3 Biomatik Gene Cloning Service Product Features and Attributes
11.12.4 Biomatik Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.12.5 Biomatik Recent Developments
11.13 OriGene
11.13.1 OriGene Corporation Information
11.13.2 OriGene Business Overview
11.13.3 OriGene Gene Cloning Service Product Features and Attributes
11.13.4 OriGene Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.13.5 OriGene Recent Developments
11.14 Macrogen
11.14.1 Macrogen Corporation Information
11.14.2 Macrogen Business Overview
11.14.3 Macrogen Gene Cloning Service Product Features and Attributes
11.14.4 Macrogen Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.14.5 Macrogen Recent Developments
11.15 abm
11.15.1 abm Corporation Information
11.15.2 abm Business Overview
11.15.3 abm Gene Cloning Service Product Features and Attributes
11.15.4 abm Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.15.5 abm Recent Developments
11.16 GeneCopoeia
11.16.1 GeneCopoeia Corporation Information
11.16.2 GeneCopoeia Business Overview
11.16.3 GeneCopoeia Gene Cloning Service Product Features and Attributes
11.16.4 GeneCopoeia Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.16.5 GeneCopoeia Recent Developments
11.17 Bioneer
11.17.1 Bioneer Corporation Information
11.17.2 Bioneer Business Overview
11.17.3 Bioneer Gene Cloning Service Product Features and Attributes
11.17.4 Bioneer Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.17.5 Bioneer Recent Developments
11.18 FASMAC
11.18.1 FASMAC Corporation Information
11.18.2 FASMAC Business Overview
11.18.3 FASMAC Gene Cloning Service Product Features and Attributes
11.18.4 FASMAC Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.18.5 FASMAC Recent Developments
11.19 ProteoGenix
11.19.1 ProteoGenix Corporation Information
11.19.2 ProteoGenix Business Overview
11.19.3 ProteoGenix Gene Cloning Service Product Features and Attributes
11.19.4 ProteoGenix Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.19.5 ProteoGenix Recent Developments
11.20 GeneCust
11.20.1 GeneCust Corporation Information
11.20.2 GeneCust Business Overview
11.20.3 GeneCust Gene Cloning Service Product Features and Attributes
11.20.4 GeneCust Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.20.5 GeneCust Recent Developments
11.21 Charles River
11.21.1 Charles River Corporation Information
11.21.2 Charles River Business Overview
11.21.3 Charles River Gene Cloning Service Product Features and Attributes
11.21.4 Charles River Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.21.5 Charles River Recent Developments
11.22 Creative Biogene
11.22.1 Creative Biogene Corporation Information
11.22.2 Creative Biogene Business Overview
11.22.3 Creative Biogene Gene Cloning Service Product Features and Attributes
11.22.4 Creative Biogene Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.22.5 Creative Biogene Recent Developments
11.23 BIONICS
11.23.1 BIONICS Corporation Information
11.23.2 BIONICS Business Overview
11.23.3 BIONICS Gene Cloning Service Product Features and Attributes
11.23.4 BIONICS Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.23.5 BIONICS Recent Developments
11.24 Genosphere
11.24.1 Genosphere Corporation Information
11.24.2 Genosphere Business Overview
11.24.3 Genosphere Gene Cloning Service Product Features and Attributes
11.24.4 Genosphere Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.24.5 Genosphere Recent Developments
11.25 Cosmogenetech
11.25.1 Cosmogenetech Corporation Information
11.25.2 Cosmogenetech Business Overview
11.25.3 Cosmogenetech Gene Cloning Service Product Features and Attributes
11.25.4 Cosmogenetech Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.25.5 Cosmogenetech Recent Developments
11.26 trenzyme
11.26.1 trenzyme Corporation Information
11.26.2 trenzyme Business Overview
11.26.3 trenzyme Gene Cloning Service Product Features and Attributes
11.26.4 trenzyme Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.26.5 trenzyme Recent Developments
11.27 PlasmidFactory
11.27.1 PlasmidFactory Corporation Information
11.27.2 PlasmidFactory Business Overview
11.27.3 PlasmidFactory Gene Cloning Service Product Features and Attributes
11.27.4 PlasmidFactory Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.27.5 PlasmidFactory Recent Developments
11.28 Oriental Yeast
11.28.1 Oriental Yeast Corporation Information
11.28.2 Oriental Yeast Business Overview
11.28.3 Oriental Yeast Gene Cloning Service Product Features and Attributes
11.28.4 Oriental Yeast Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.28.5 Oriental Yeast Recent Developments
11.29 Protein Express
11.29.1 Protein Express Corporation Information
11.29.2 Protein Express Business Overview
11.29.3 Protein Express Gene Cloning Service Product Features and Attributes
11.29.4 Protein Express Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.29.5 Protein Express Recent Developments
11.30 UNITECH
11.30.1 UNITECH Corporation Information
11.30.2 UNITECH Business Overview
11.30.3 UNITECH Gene Cloning Service Product Features and Attributes
11.30.4 UNITECH Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.30.5 UNITECH Recent Developments
11.31 Synplogen
11.31.1 Synplogen Corporation Information
11.31.2 Synplogen Business Overview
11.31.3 Synplogen Gene Cloning Service Product Features and Attributes
11.31.4 Synplogen Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.31.5 Synplogen Recent Developments
11.32 Tri-i Biotech
11.32.1 Tri-i Biotech Corporation Information
11.32.2 Tri-i Biotech Business Overview
11.32.3 Tri-i Biotech Gene Cloning Service Product Features and Attributes
11.32.4 Tri-i Biotech Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.32.5 Tri-i Biotech Recent Developments
11.33 1st BASE
11.33.1 1st BASE Corporation Information
11.33.2 1st BASE Business Overview
11.33.3 1st BASE Gene Cloning Service Product Features and Attributes
11.33.4 1st BASE Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.33.5 1st BASE Recent Developments
11.34 Wuhan GeneCreate
11.34.1 Wuhan GeneCreate Corporation Information
11.34.2 Wuhan GeneCreate Business Overview
11.34.3 Wuhan GeneCreate Gene Cloning Service Product Features and Attributes
11.34.4 Wuhan GeneCreate Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.34.5 Wuhan GeneCreate Recent Developments
11.35 Genome Meditech
11.35.1 Genome Meditech Corporation Information
11.35.2 Genome Meditech Business Overview
11.35.3 Genome Meditech Gene Cloning Service Product Features and Attributes
11.35.4 Genome Meditech Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.35.5 Genome Meditech Recent Developments
11.36 Hanbio
11.36.1 Hanbio Corporation Information
11.36.2 Hanbio Business Overview
11.36.3 Hanbio Gene Cloning Service Product Features and Attributes
11.36.4 Hanbio Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.36.5 Hanbio Recent Developments
11.37 NewOneBio
11.37.1 NewOneBio Corporation Information
11.37.2 NewOneBio Business Overview
11.37.3 NewOneBio Gene Cloning Service Product Features and Attributes
11.37.4 NewOneBio Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.37.5 NewOneBio Recent Developments
11.38 Aragen
11.38.1 Aragen Corporation Information
11.38.2 Aragen Business Overview
11.38.3 Aragen Gene Cloning Service Product Features and Attributes
11.38.4 Aragen Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.38.5 Aragen Recent Developments
11.39 Barcode Biosciences
11.39.1 Barcode Biosciences Corporation Information
11.39.2 Barcode Biosciences Business Overview
11.39.3 Barcode Biosciences Gene Cloning Service Product Features and Attributes
11.39.4 Barcode Biosciences Gene Cloning Service Revenue and Gross Margin (2021-2026)
11.39.5 Barcode Biosciences Recent Developments

12 Gene Cloning Service Value Chain and Ecosystem Analysis
12.1 Gene Cloning Service Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Gene Cloning Service Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Gene Cloning Service Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Gene Cloning Service Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Gene Cloning Service Market Size Growth Rate by Project Complexity, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Gene Cloning Service Market Size Growth Rate by Construct Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Gene Cloning Service Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Gene Cloning Service Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Gene Cloning Service Revenue by Region (US$ Million), 2021-2026
Table 7. Global Gene Cloning Service Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Gene Cloning Service Revenue by Players (US$ Million), 2021-2026
Table 10. Global Gene Cloning Service Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Gene Cloning Service Revenue, 2025
Table 13. Global Gene Cloning Service Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Gene Cloning Service Companies Headquarters
Table 15. Global Gene Cloning Service Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Gene Cloning Service Revenue by Type (US$ Million), 2021-2026
Table 19. Global Gene Cloning Service Revenue by Type (US$ Million), 2027-2032
Table 20. Global Gene Cloning Service Revenue by Project Complexity (US$ Million), 2021-2026
Table 21. Global Gene Cloning Service Revenue by Project Complexity (US$ Million), 2027-2032
Table 22. Global Gene Cloning Service Revenue by Construct Type (US$ Million), 2021-2026
Table 23. Global Gene Cloning Service Revenue by Construct Type (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Gene Cloning Service Revenue by Application (US$ Million), 2021-2026
Table 26. Global Gene Cloning Service Revenue by Application (US$ Million), 2027-2032
Table 27. Gene Cloning Service High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Gene Cloning Service Growth Accelerators and Market Barriers
Table 31. North America Gene Cloning Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Gene Cloning Service Growth Accelerators and Market Barriers
Table 33. Europe Gene Cloning Service Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Gene Cloning Service Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Gene Cloning Service Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Gene Cloning Service Investment Opportunities and Key Challenges
Table 37. Central and South America Gene Cloning Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Gene Cloning Service Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Gene Cloning Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. GenScript Biotech Corporation Corporation Information
Table 41. GenScript Biotech Corporation Description and Major Businesses
Table 42. GenScript Biotech Corporation Product Features and Attributes
Table 43. GenScript Biotech Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. GenScript Biotech Corporation Revenue Proportion by Product in 2025
Table 45. GenScript Biotech Corporation Revenue Proportion by Application in 2025
Table 46. GenScript Biotech Corporation Revenue Proportion by Geographic Area in 2025
Table 47. GenScript Biotech Corporation Gene Cloning Service SWOT Analysis
Table 48. GenScript Biotech Corporation Recent Developments
Table 49. Danaher Corporation Information
Table 50. Danaher Description and Major Businesses
Table 51. Danaher Product Features and Attributes
Table 52. Danaher Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Danaher Revenue Proportion by Product in 2025
Table 54. Danaher Revenue Proportion by Application in 2025
Table 55. Danaher Revenue Proportion by Geographic Area in 2025
Table 56. Danaher Gene Cloning Service SWOT Analysis
Table 57. Danaher Recent Developments
Table 58. Twist Bioscience Corporation Information
Table 59. Twist Bioscience Description and Major Businesses
Table 60. Twist Bioscience Product Features and Attributes
Table 61. Twist Bioscience Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Twist Bioscience Revenue Proportion by Product in 2025
Table 63. Twist Bioscience Revenue Proportion by Application in 2025
Table 64. Twist Bioscience Revenue Proportion by Geographic Area in 2025
Table 65. Twist Bioscience Gene Cloning Service SWOT Analysis
Table 66. Twist Bioscience Recent Developments
Table 67. Thermo Fisher Corporation Information
Table 68. Thermo Fisher Description and Major Businesses
Table 69. Thermo Fisher Product Features and Attributes
Table 70. Thermo Fisher Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Thermo Fisher Revenue Proportion by Product in 2025
Table 72. Thermo Fisher Revenue Proportion by Application in 2025
Table 73. Thermo Fisher Revenue Proportion by Geographic Area in 2025
Table 74. Thermo Fisher Gene Cloning Service SWOT Analysis
Table 75. Thermo Fisher Recent Developments
Table 76. Azenta Corporation Information
Table 77. Azenta Description and Major Businesses
Table 78. Azenta Product Features and Attributes
Table 79. Azenta Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Azenta Revenue Proportion by Product in 2025
Table 81. Azenta Revenue Proportion by Application in 2025
Table 82. Azenta Revenue Proportion by Geographic Area in 2025
Table 83. Azenta Gene Cloning Service SWOT Analysis
Table 84. Azenta Recent Developments
Table 85. Tsingke Biotechnology Corporation Information
Table 86. Tsingke Biotechnology Description and Major Businesses
Table 87. Tsingke Biotechnology Product Features and Attributes
Table 88. Tsingke Biotechnology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Tsingke Biotechnology Recent Developments
Table 90. VectorBuilder Corporation Information
Table 91. VectorBuilder Description and Major Businesses
Table 92. VectorBuilder Product Features and Attributes
Table 93. VectorBuilder Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. VectorBuilder Recent Developments
Table 95. Synbio Technologies Corporation Information
Table 96. Synbio Technologies Description and Major Businesses
Table 97. Synbio Technologies Product Features and Attributes
Table 98. Synbio Technologies Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Synbio Technologies Recent Developments
Table 100. General Biol Corporation Information
Table 101. General Biol Description and Major Businesses
Table 102. General Biol Product Features and Attributes
Table 103. General Biol Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. General Biol Recent Developments
Table 105. ATUM Corporation Information
Table 106. ATUM Description and Major Businesses
Table 107. ATUM Product Features and Attributes
Table 108. ATUM Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. ATUM Recent Developments
Table 110. Bio Basic Corporation Information
Table 111. Bio Basic Description and Major Businesses
Table 112. Bio Basic Product Features and Attributes
Table 113. Bio Basic Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Bio Basic Recent Developments
Table 115. Biomatik Corporation Information
Table 116. Biomatik Description and Major Businesses
Table 117. Biomatik Product Features and Attributes
Table 118. Biomatik Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Biomatik Recent Developments
Table 120. OriGene Corporation Information
Table 121. OriGene Description and Major Businesses
Table 122. OriGene Product Features and Attributes
Table 123. OriGene Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. OriGene Recent Developments
Table 125. Macrogen Corporation Information
Table 126. Macrogen Description and Major Businesses
Table 127. Macrogen Product Features and Attributes
Table 128. Macrogen Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Macrogen Recent Developments
Table 130. abm Corporation Information
Table 131. abm Description and Major Businesses
Table 132. abm Product Features and Attributes
Table 133. abm Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. abm Recent Developments
Table 135. GeneCopoeia Corporation Information
Table 136. GeneCopoeia Description and Major Businesses
Table 137. GeneCopoeia Product Features and Attributes
Table 138. GeneCopoeia Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. GeneCopoeia Recent Developments
Table 140. Bioneer Corporation Information
Table 141. Bioneer Description and Major Businesses
Table 142. Bioneer Product Features and Attributes
Table 143. Bioneer Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Bioneer Recent Developments
Table 145. FASMAC Corporation Information
Table 146. FASMAC Description and Major Businesses
Table 147. FASMAC Product Features and Attributes
Table 148. FASMAC Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. FASMAC Recent Developments
Table 150. ProteoGenix Corporation Information
Table 151. ProteoGenix Description and Major Businesses
Table 152. ProteoGenix Product Features and Attributes
Table 153. ProteoGenix Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. ProteoGenix Recent Developments
Table 155. GeneCust Corporation Information
Table 156. GeneCust Description and Major Businesses
Table 157. GeneCust Product Features and Attributes
Table 158. GeneCust Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. GeneCust Recent Developments
Table 160. Charles River Corporation Information
Table 161. Charles River Description and Major Businesses
Table 162. Charles River Product Features and Attributes
Table 163. Charles River Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Charles River Recent Developments
Table 165. Creative Biogene Corporation Information
Table 166. Creative Biogene Description and Major Businesses
Table 167. Creative Biogene Product Features and Attributes
Table 168. Creative Biogene Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. Creative Biogene Recent Developments
Table 170. BIONICS Corporation Information
Table 171. BIONICS Description and Major Businesses
Table 172. BIONICS Product Features and Attributes
Table 173. BIONICS Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. BIONICS Recent Developments
Table 175. Genosphere Corporation Information
Table 176. Genosphere Description and Major Businesses
Table 177. Genosphere Product Features and Attributes
Table 178. Genosphere Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Genosphere Recent Developments
Table 180. Cosmogenetech Corporation Information
Table 181. Cosmogenetech Description and Major Businesses
Table 182. Cosmogenetech Product Features and Attributes
Table 183. Cosmogenetech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Cosmogenetech Recent Developments
Table 185. trenzyme Corporation Information
Table 186. trenzyme Description and Major Businesses
Table 187. trenzyme Product Features and Attributes
Table 188. trenzyme Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. trenzyme Recent Developments
Table 190. PlasmidFactory Corporation Information
Table 191. PlasmidFactory Description and Major Businesses
Table 192. PlasmidFactory Product Features and Attributes
Table 193. PlasmidFactory Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. PlasmidFactory Recent Developments
Table 195. Oriental Yeast Corporation Information
Table 196. Oriental Yeast Description and Major Businesses
Table 197. Oriental Yeast Product Features and Attributes
Table 198. Oriental Yeast Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. Oriental Yeast Recent Developments
Table 200. Protein Express Corporation Information
Table 201. Protein Express Description and Major Businesses
Table 202. Protein Express Product Features and Attributes
Table 203. Protein Express Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. Protein Express Recent Developments
Table 205. UNITECH Corporation Information
Table 206. UNITECH Description and Major Businesses
Table 207. UNITECH Product Features and Attributes
Table 208. UNITECH Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. UNITECH Recent Developments
Table 210. Synplogen Corporation Information
Table 211. Synplogen Description and Major Businesses
Table 212. Synplogen Product Features and Attributes
Table 213. Synplogen Revenue (US$ Million) and Gross Margin (2021-2026)
Table 214. Synplogen Recent Developments
Table 215. Tri-i Biotech Corporation Information
Table 216. Tri-i Biotech Description and Major Businesses
Table 217. Tri-i Biotech Product Features and Attributes
Table 218. Tri-i Biotech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 219. Tri-i Biotech Recent Developments
Table 220. 1st BASE Corporation Information
Table 221. 1st BASE Description and Major Businesses
Table 222. 1st BASE Product Features and Attributes
Table 223. 1st BASE Revenue (US$ Million) and Gross Margin (2021-2026)
Table 224. 1st BASE Recent Developments
Table 225. Wuhan GeneCreate Corporation Information
Table 226. Wuhan GeneCreate Description and Major Businesses
Table 227. Wuhan GeneCreate Product Features and Attributes
Table 228. Wuhan GeneCreate Revenue (US$ Million) and Gross Margin (2021-2026)
Table 229. Wuhan GeneCreate Recent Developments
Table 230. Genome Meditech Corporation Information
Table 231. Genome Meditech Description and Major Businesses
Table 232. Genome Meditech Product Features and Attributes
Table 233. Genome Meditech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 234. Genome Meditech Recent Developments
Table 235. Hanbio Corporation Information
Table 236. Hanbio Description and Major Businesses
Table 237. Hanbio Product Features and Attributes
Table 238. Hanbio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 239. Hanbio Recent Developments
Table 240. NewOneBio Corporation Information
Table 241. NewOneBio Description and Major Businesses
Table 242. NewOneBio Product Features and Attributes
Table 243. NewOneBio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 244. NewOneBio Recent Developments
Table 245. Aragen Corporation Information
Table 246. Aragen Description and Major Businesses
Table 247. Aragen Product Features and Attributes
Table 248. Aragen Revenue (US$ Million) and Gross Margin (2021-2026)
Table 249. Aragen Recent Developments
Table 250. Barcode Biosciences Corporation Information
Table 251. Barcode Biosciences Description and Major Businesses
Table 252. Barcode Biosciences Product Features and Attributes
Table 253. Barcode Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 254. Barcode Biosciences Recent Developments
Table 255. Technologies, Platforms and Infrastructure
Table 256. Distributors List
Table 257. Market Trends and Market Evolution
Table 258. Market Drivers and Opportunities
Table 259. Market Challenges, Risks, and Restraints
Table 260. Research Programs/Design for This Report
Table 261. Key Data Information from Secondary Sources
Table 262. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Gene Cloning Service Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Template-based Cloning Product Picture
Figure 3. Subcloning Product Picture
Figure 4. Gene Synthesis and Cloning Product Picture
Figure 5. Custom Vector Construction Product Picture
Figure 6. Others Product Picture
Figure 7. Global Gene Cloning Service Market Size Growth Rate by Project Complexity, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. Standard Cloning Product Picture
Figure 9. Custom Vector Modification Product Picture
Figure 10. Multi-fragment Assembly Product Picture
Figure 11. Difficult DNA Constructs Product Picture
Figure 12. High-throughput Construct Projects Product Picture
Figure 13. Global Gene Cloning Service Market Size Growth Rate by Construct Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 14. Standard Cloning Plasmids Product Picture
Figure 15. Protein Expression Vectors Product Picture
Figure 16. Reporter and Functional Vectors Product Picture
Figure 17. Gene Editing Constructs Product Picture
Figure 18. Viral Vector Plasmids Product Picture
Figure 19. Global Gene Cloning Service Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 20. Basic and Functional Research
Figure 21. Protein and Antibody Engineering
Figure 22. Synthetic Biology and Metabolic Engineering
Figure 23. Others
Figure 24. Gene Cloning Service Report Years Considered
Figure 25. Global Gene Cloning Service Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 26. Global Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 27. Global Gene Cloning Service Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 28. Global Gene Cloning Service Revenue-Based Market Share by Region (2021-2032)
Figure 29. Global Gene Cloning Service Revenue-Based Market Share Ranking (2025)
Figure 30. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 31. Template-based Cloning Revenue-Based Market Share by Player in 2025
Figure 32. Subcloning Revenue-Based Market Share by Player in 2025
Figure 33. Gene Synthesis and Cloning Revenue-Based Market Share by Player in 2025
Figure 34. Custom Vector Construction Revenue-Based Market Share by Player in 2025
Figure 35. Others Revenue-Based Market Share by Player in 2025
Figure 36. Global Gene Cloning Service Revenue-Based Market Share by Type (2021-2032)
Figure 37. Global Gene Cloning Service Revenue-Based Market Share by Project Complexity (2021-2032)
Figure 38. Global Gene Cloning Service Revenue-Based Market Share by Construct Type (2021-2032)
Figure 39. Global Gene Cloning Service Revenue-Based Market Share by Application (2021-2032)
Figure 40. North America Gene Cloning Service Revenue YoY (US$ Million), 2021-2032
Figure 41. North America Top 5 Players Gene Cloning Service Revenue (US$ Million) in 2025
Figure 42. North America Gene Cloning Service Revenue (US$ Million) by Application (2021-2032)
Figure 43. US Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 44. Canada Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 45. Mexico Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 46. Europe Gene Cloning Service Revenue YoY (US$ Million), 2021-2032
Figure 47. Europe Top 5 Players Gene Cloning Service Revenue (US$ Million) in 2025
Figure 48. Europe Gene Cloning Service Revenue (US$ Million) by Application (2021-2032)
Figure 49. Germany Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 50. France Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 51. U.K. Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 52. Italy Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 53. Russia Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 54. Asia-Pacific Gene Cloning Service Revenue YoY (US$ Million), 2021-2032
Figure 55. Asia-Pacific Top 8 Players Gene Cloning Service Revenue (US$ Million) in 2025
Figure 56. Asia-Pacific Gene Cloning Service Revenue (US$ Million) by Application (2021-2032)
Figure 57. Indonesia Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 58. Japan Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 59. South Korea Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 60. Australia Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 61. India Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 62. Indonesia Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 63. Vietnam Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 64. Malaysia Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 65. Philippines Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 66. Singapore Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 67. Central and South America Gene Cloning Service Revenue YoY (US$ Million), 2021-2032
Figure 68. Central and South America Top 5 Players Gene Cloning Service Revenue (US$ Million) in 2025
Figure 69. Central and South America Gene Cloning Service Revenue (US$ Million) by Application (2021-2032)
Figure 70. Brazil Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 71. Argentina Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 72. Middle East and Africa Gene Cloning Service Revenue YoY (US$ Million), 2021-2032
Figure 73. Middle East and Africa Top 5 Players Gene Cloning Service Revenue (US$ Million) in 2025
Figure 74. Middle East and Africa Gene Cloning Service Revenue (US$ Million) by Application (2021-2032)
Figure 75. GCC Countries Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 76. Israel Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 77. Egypt Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 78. South Africa Gene Cloning Service Revenue (US$ Million), 2021-2032
Figure 79. Gene Cloning Service Value Chain Mapping
Figure 80. Channels of Distribution (Direct Vs Distribution)
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed